# Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

> **NCT04305054** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 315 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Vibostolimab
- **BIOLOGICAL:** Pembrolizumab/Quavonlimab
- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Favezelimab/Pembrolizumab
- **DRUG:** ATRA

## Key facts

- **NCT ID:** NCT04305054
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-05-20
- **Target enrollment:** 315 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04305054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04305054, "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04305054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*